Revealing Hidden Pathologies, Breaking Imaging Limits: Biomarker-Activated Nanoprobes Uncover Early Arthritis and...

Arthritis, a prevalent degenerative joint disorder characterized by progressive pain, swelling, and stiffness, frequently progresses to irreversible joint deformity and functional impairment. Early diagnosis remains critical yet challenging, as conventional clinical imaging techniques often fail to detect pathological changes until advanced stages, significantly compromising therapeutic outcomes. To address these limitations, engineered nanoprobes have emerged as next-generation diagnostic tools leveraging dual targeting mechanisms: passive accumulation via the enhanced permeability and retention effect in arthritic tissues, and active targeting through surface-conjugated antibodies or disease-specific ligands. These nanostructures exhibit remarkable adaptability, with designs responsive to pathophysiological cues such as synovial pH fluctuations, local hyperthermia, oxidative stress and disease-specific biomarkers. Modern nanoprobe platforms integrate multimodal imaging capabilities, synergizing near-infrared II fluorescence (NIR-II), photoacoustic imaging, and magnetic resonance imaging (MRI) to achieve unprecedented spatial resolution and detection sensitivity. Innovatively, certain theranostic nanoprobes coload therapeutic agents with contrast media, enabling real-time visualization of drug delivery kinetics and treatment efficacy. Their biomarker-specific responsiveness permits dynamic monitoring of early inflammatory cascades and subclinical cartilage degradation─processes undetectable by traditional diagnostics. This review systematically examines cutting-edge nanoprobe designs that simultaneously detect oxidative stress markers, microenvironmental changes, and arthritis-specific biomarkers through spatiotemporally resolved multimodal imaging. We highlight their capacity to transform molecular signatures into quantifiable imaging signals, thereby facilitating precision diagnosis, longitudinal disease tracking, and personalized therapeutic regimens. While preclinical studies demonstrate exceptional promise, key challenges persist in optimizing biocompatibility profiles, ensuring precise targeting efficiency, and translating these technologies into clinical practice. Future advancements will require interdisciplinary collaboration to refine material engineering strategies and validate clinical utility, ultimately positioning nanoprobes as indispensable tools for revolutionizing arthritis management.